SynthesisFrontiers in oncology2026
Impact of metastatic pattern and histologic subtype on PD-(L)1 inhibitor efficacy in HER2-negative advanced gastric and gastroesophageal cancer: a meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The therapeutic benefit of PD-(L)1 blockade in advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJ) may vary by niche and tumor biology. We conducted a meta-analysis to evaluate how metastatic site and Lauren histologic subtype influence survival outcomes in HER2-negative GC/GEJ treated with PD-(L)1 inhibitor-based chemoimmunotherapy. Methods: A systematic PubMed, MEDLINE, and Embase search identified phase III randomized controlled trials published between 2021 and 2025 comparing IO plus platinum-fluoropyrimidine chemotherapy vs. chemotherapy alone in HER2-negative metastatic or unresectable GC/GEJ. Hazard ratios (HRs) for overall survival (OS) were pooled using random-effects models in the intention-to-treat (ITT) population and prespecified subgroups, including liver metastases (LM), peritoneal metastases (PM), Lauren histologic subtype, and PD-L1 expression assessed by combined positive score (CPS) or tumor area positivity score (TAPS). Between-study heterogeneity was assessed using the I² statistic, and analyses were conducted in R. Results: Six global trials including 5, 410 patients (CHECKMATE 649, ATTRACTION-4, KEYNOTE-859, ORIENT-16, RATIONALE-305, AND GEMSTONE-303) were analyzed. Overall, IO plus CT significantly improved OS compared with CT alone (HR 0.79, 95% CI 0.75-0.84; p<0.001). Survival benefit was observed in patients with and without LM (HR 0.75 and 0.82), whereas patients with PM derived limited benefit (HR 0.93). Intestinal-type tumors achieved greater OS improvement than diffuse-type tumors (HR 0.78 vs 0.87). PD-L1 CPS ≥5 predicted superior OS benefit (HR 0.70). Grade ≥3 adverse events were infrequent and hematologic. Conclusion: First-line chemoimmunotherapy prolongs survival in HER2-negative GC/GEJ. Reduced benefit in diffuse-type and peritoneal disease underscores heterogeneity and supports site- and histology-specific strategies. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251174893.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.